Dr. Sun, serving as the Chief Business Officer (CBO), currently leads Global Business Development and Alliance Management at Hansoh Pharmaceutical Group. Over the past three years, he and his team have accomplished over 20 licensing and collaboration deals, including two recent out-bound licensing agreements with GSK. Dr. Sun also plays a pivotal role in supporting Hansoh R&D by evaluating and accessing new technologies, platforms, and modalities.

Prior to joining Hansoh, Dr. Sun dedicated 19 years to Daiichi Sankyo, where he spent the initial five years in R&D, contributing to activities ranging from target discovery to clinical development. Transitioning to the Business Development division, he successfully identified, evaluated, and negotiated numerous partnership opportunities.

Dr. Sun holds an MD from Peking University Medical School, as well as master’s and doctoral degrees in Cell Biochemistry from the University of Tokyo. Additionally, he earned an MBA from Columbia Business School.